{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:22:01Z","timestamp":1791908521046,"version":"4.3.4"},"reference-count":71,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,4,24]],"date-time":"2007-04-24T00:00:00Z","timestamp":1177372800000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drug Reviews"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Natalizumab (Tysabri\u00ae) was the first adhesion molecule antagonist to make it into clinical trial for patients with multiple sclerosis (MS) and other inflammatory disorders. Natalizumab is a humanized recombinant monoclonal antibody (MAb) that binds to the alpha (\u03b1)<jats:sub>4<\/jats:sub> chain of the \u03b1<jats:sub>4<\/jats:sub> beta (\u03b2)<jats:sub>1<\/jats:sub> (very late activating antigen 4; VLA\u20104) and \u03b1<jats:sub>4<\/jats:sub>\u03b2<jats:sub>7<\/jats:sub> integrins. The scientific rationale for natalizumab therapy is the reduction of leukocyte extravasation into peripheral tissues. Natalizumab, like other VLA\u20104 antagonists, may also interfere with the activation of T lymphocytes in secondary lymphoid organs and their reactivation in the central nervous system (CNS).<\/jats:p><jats:p>Shortly after its approval for the treatment of relapsing\u2010remitting MS (RR\u2010MS), three patients who were treated with natalizumab in the setting of clinical trials developed progressive multifocal leukoencephalopathy (PML), an opportunistic infection of the brain with the polyoma virus JC. It remains to be elucidated why the use of this VLA\u20104 antagonist is associated with an increased incidence of PML. Natalizumab was recently reapproved for the treatment of relapsing forms of MS. In this review, we outline the scientific rationale for using natalizumab in MS and other inflammatory disorders. In addition, an overview of pharmacological properties, clinical efficacy, safety, and toxicology of natalizumab is provided.<\/jats:p>","DOI":"10.1111\/j.1527-3458.2007.00003.x","type":"journal-article","created":{"date-parts":[[2007,5,6]],"date-time":"2007-05-06T01:46:54Z","timestamp":1178416014000},"page":"79-95","source":"Crossref","is-referenced-by-count":103,"title":["Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri\u00ae) in Inflammatory Diseases"],"prefix":"10.1111","volume":"13","author":[{"given":"Olaf","family":"St\u00fcve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,4,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1352(200101\/02)14:1<62::AID-JMR520>3.0.CO;2-T"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1424"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701522"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1179\/016164106X98189"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1179\/016164106X98198"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2003.08.003"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04725-5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.3.785"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1197"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0730-725X(96)00018-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3276004"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00876"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.172.4.1025"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00971-6"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431301"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390304"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00245-3"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000237641.33768.8d"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200404160"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1646"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051782"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.6.3301"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18604.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1006\/meth.1999.0926"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-1997-8102"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mn.7800194"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.113.20.3563"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1275"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020696"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.1992.10647886"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(04)00077-9"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20859"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.4.1045"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000128136.79044.D6"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1223oa"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(02)00273-4"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.06.018"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00505-2"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1005-1275"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.61.5.689"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.58.1.39"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068002"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.4049\/jimmunol.155.6.2938","article-title":"Role of the VLA\u20104 molecule in T cell costimulation: Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA\u20104","volume":"155","author":"Sato T","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1194"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.5.1072"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.1.59"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1990.tb00563.x"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040424"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1997.6.563"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.10.1383"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20858"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(95)90130-2"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.655"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.4.679"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11717"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0974"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.466"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12440"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051586"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1084oa"},{"key":"e_1_2_8_67_1","first-page":"105","article-title":"Rescue from apoptosis in early (CD34\u2010selected) versus late (non\u2010CD34\u2010selected) human hematopoietic cells by very late antigen 4\u2010 and vascular cell adhesion molecule (VCAM) 1\u2010dependent adhesion to bone marrow stromal cells","volume":"9","author":"Wang MW","year":"1998","journal-title":"Cell Growth Differ"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-440X(94)90267-4"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.3.842"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/356063a0"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054693"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.08.040190.003051"}],"container-title":["CNS Drug Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-3458.2007.00003.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-3458.2007.00003.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:34:30Z","timestamp":1697150070000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-3458.2007.00003.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1111\/j.1527-3458.2007.00003.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-3458.2007.00003.x","archive":["Portico"],"relation":{},"ISSN":["1080-563X","1527-3458"],"issn-type":[{"value":"1080-563X","type":"print"},{"value":"1527-3458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}